We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Lethal Immune Myocarditis and Myasthenia Gravis Due to Anti-PD-1 Treatment for a Bladder Cancer Patient: A Case Report and Possible Treatment Inspiration.
- Authors
Gao, Pan; Li, Xinyu; He, Ziqiu; Zhang, Hongbo; Zhang, Zhi; Liu, Zonglai
- Abstract
Immune checkpoint inhibitors (ICI) have become a new hope for many patients with advanced cancer by blocking tumor immune escape. Bladder cancer is a common malignant tumor of the urinary tract epithelium that often relapses and metastasizes after surgery, chemotherapy, and radiotherapy. Immunotherapy has dramatically improved patient survival rates and clinical benefits as a new, potentially effective therapy. However, avoidance of various immune-related adverse events (irAEs) remains an implausible idea. ICI-induced myocarditis is different from viral myocarditis, and mortality is still high with the current treatment. We report the case of an 82-year-old female patient with ICI-induced fulminant myocarditis and myasthenia gravis. Although she actively accepted the current mainstream treatment for immune-related myocarditis and myasthenia, she died of heart and respiratory failure. Analyzing and reporting the patient's disease development process and the changes in related indicators may help peers gain a deeper understanding of immune-related adverse events and reduce the mortality of immune-related myocarditis.
- Subjects
MYASTHENIA gravis; DRUG side effects; MYOCARDITIS; IMMUNE checkpoint inhibitors; BLADDER cancer; CANCER patients
- Publication
International Medical Case Reports Journal, 2024, Vol 17, p359
- ISSN
1179-142X
- Publication type
Case Study
- DOI
10.2147/IMCRJ.S449525